Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against 
                   by unknown
Song et al. BMC Infectious Diseases  (2017) 17:19 
DOI 10.1186/s12879-016-2147-1RESEARCH ARTICLE Open AccessVaccination with toxofilin DNA in
combination with an alum-
monophosphoryl lipid A mixed adjuvant
induces significant protective immunity
against Toxoplasma gondii
Pengxia Song1, Shenyi He1*, Aihua Zhou3, Gang Lv1, Jingjing Guo1, Jian Zhou2, Yali Han1, Huaiyu Zhou1,
Zhen Hao1 and Hua Cong1Abstract
Background: A widely prevalent disease, toxoplasmosis poses serious health threats to both humans and animals;
therefore, development of an ideal DNA vaccine against Toxoplasma gondii is needed eagerly. The purpose of the
present study is to assess the protective efficacy of a DNA vaccine encoding the T. gondii toxofilin gene
(pEGFP-toxofilin). In addition, toxofilin DNA vaccine combined with the individual adjuvants, alum or
monophosphoryl lipid A (MPLA), or a mixture of alum-MPLA adjuvant were screened for their ability to enhance
antibody responses.
Methods: Using bioinformatics, we analyzed the gene and amino acid sequences of the toxofilin protein,
recognizing and identifying several potential linear B and T helper (Th)-1 cell epitopes. BALB/c mice were
immunized three times with either toxofilin DNA vaccine alone or in combination with the adjuvants such as alum,
MPLA or an alum-MPLA mixture. The systemic immune response was evaluated by cytokine, the percentage of CD4
(+) and CD8 (+) T cells and specific antibody measurement. Two weeks after the last immunization, protective
efficacy was evaluated by challenging intraperitoneally with 1 × 104 tachyzoites of T. gondii or intragastrically with
20 cysts of T. gondii PRU strain.
Results: All experimentally immunized mice developed strong humoral and cellular immune responses compared
with the control groups. Moreover, by comparison with the non-adjuvant toxofilin DNA vaccine group, adding
alum adjuvant to toxofilin DNA vaccine resulted in an increase in humoral response and a skewed Th2 response.
However, the MPLA adjuvant with toxofilin DNA vaccine induced significantly enhanced humoral and Th1-biased
immune responses. Importantly, the co-administration of alum-MPLA adjuvant in combination with the toxofilin
DNA vaccine shifted the Th2 immune response to a Th1 response compared with the alum-toxofilin group, and
elicited the strongest humoral and Th1 responses among all the groups. At the same time, a longer survival time
and less cyst amounts against T. gondii infection were also observed in the alum-MPLA-toxofilin group in
comparison with single or no adjuvant groups.
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Conclusions: Toxoplasma gondii toxofilin is a promising vaccine candidate that warrants further development.
Co-administration of the alum-MPLA adjuvant mixture with DNA vaccine could effectively enhance immunogenicity
and strongly skew the cellular immune response towards a Th1 phenotype.
Keywords: Toxoplasma gondii, Toxofilin, Bioinformatics, DNA vaccine, AdjuvantBackground
Toxoplasma gondii is an obligate intracellular protozoan
parasite [1]. It has a complex life cycle, infecting a broad
host range of mammals and birds as intermediate hosts
but with felids as the only definitive hosts [2]. The
T.gondii has a wide range of distribution and high infec-
tion rates in many parts of the world and a third of
population is infected [3, 4]. Although infection with T.
gondii may be asymptomatic in immunocompetent indi-
viduals, severe disease can develop in immunocomprom-
ised patients or fetuses of seronegative women
undergoing primary infection during pregnancy [4, 5].
The primary strategy for the treatment of toxoplasmo-
sis is chemical drugs; however, such drugs have many
drawbacks, including poor tolerance, side effects, and
the development of drug resistance and are ineffective
for the treatment of T. gondii tissue cysts in warm-
blooded animals. Besides, they can’t prevent reinfection
[6]. Therefore, the development of an effective and safe
vaccine against toxoplasmosis is of great importance to
prevent the continued spread of this disease. In the past
15 years, significant progresses have been made in the
development of vaccine [7]. DNA vaccinations against
toxoplasmosis are well known to induce Th1 immune
response [8]. Several single-antigen vaccines such as
ROP8, TgCyP, and GRA6, have been successful in facili-
tating survival following a lethal dose of infection
challenge, with a range of survival rates from 37.5 to
50.0% [9–11]. However, the development of a higher effi-
cacy vaccine remains a vital challenge in light of the
persistent nature of chronic toxoplasmosis.
Toxofilin, which was discovered in the rhoptry
proteome, was originally based on its role in binding
and the regulation of host actin dynamics. Recently,
toxofilin was crystallized in complex with mammalian
actin, establishing the interaction between the parasite
and host protein [12]. Toxofilin is an internal protein.
During the parasites invade into the host cell, the
protein was secreted to host cell to facilitate vacuole
folding and tachytozoites invasion. In addition, anti-
toxofilin or anti-HA antibodies was detected in in-
fected host cells by fluorescence microscopy imaging
[13]. However, there is thus far no evidence as to
whether toxofilin DNA vaccine can induce significanthumoral and cellular responses in mice and the
protective efficacy of toxofilin DNA as a vaccine
against T. gondii remains unclear.
A good vaccine also depends on the choice of
adjuvants which play a key factor in dictating the effect-
iveness of the immune response [14, 15]. Aluminum
salts (alum) are the most widely used of adjuvants in
vaccine development. However, alum which is used as
an adjuvant has several limitations. Obviously, alum-
based adjuvants tend to T helper (Th) 2 immunity and
are incompatible with small peptide antigens [16]. With
the aim of developing a transmission-blocking T.gondii
vaccine, the application of compound adjuvant has
leaded the vaccine development to a new era, resulting
in a stronger immune response through a synergistic
effect. This strategy incorporating a combination of
adjuvants (monophosphoryl lipid A (MPLA) and alum)
is proven to be effective [17, 18]. MPLA as an adjuvant
system have additive effects, especially intracellular pro-
cessing of Th1 antigens by the major histocompatibility
complex. At the same time, MPLA can enhance antigen-
specific induction of antibodies to a variety of antigens
[19, 20].
To our knowledge, no report has described a toxofilin-
based vaccination regimen against T. gondii. In this
study, the linear B- and Th-cell epitopes of toxofilin
protein were analyzed using bioinformatics. Further-
more, through analysis of the generated peptide segment
tables, we constructed a eukaryotic plasmid pEGFP-
toxofilin and investigated the overall survival, cysts bur-
den and levels of humoral and cellular immune
responses elicited by toxofilin DNA vaccine alone or in
combination with one and more adjuvants following




The gene and amino acid sequences of toxofilin were
identified from GenBank (http://www.ncbi.nlm.nih.gov/
genbank), the primary characteristics of the gene encoding
protein were analyzed by ProtParam (http://web.expa-
sy.org/protparam/), the primary amino acid sequences of
toxofilin homologs were downloaded from the National
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sequence alignment was generated using the Clustal W
method in DNASTAR MegAlign software.
Bioinformatic tools for predicting potential B-cell-binding
epitopes
B-cell epitopes are recognized in their native structure
by B-cell receptors or antibodies. Continuous B cell
epitope prediction is mainly according to the amino acid
properties. However the discontinuous B cell epitope
prediction requires 3D structure of the antigen [21–23].
In this study, the complete amino acid sequence and the
secondary structure of toxofilin were analyzed using
DNASTAR [24]. A higher score of toxofilin corre-
sponded to a higher probability of the residue being
involved in the epitope, using DNAMA software. The
SOPMA and I-TASSER online services were used to
construct the three-dimensional (3D) structures of the
toxofilin epitopes [25].
Identification of the Th-cell epitopes
The Immune Epitope Database online service (http://
tools.immuneepitope.org/analyze/html/mhc_II_binding.
html) was used to predict MHC II molecules of toxofi-
lin. It is important to note, however, that such binding
to MHC is necessary but not sufficient for recognition
by T cells [26].
Cell culture
HEK239T cells stored at −80 °C were thawed for 1 min
at 37 °C followed by culture in Dulbecco’s modified
Eagle’s medium (DMEM; GIBCO) with 10% fetal bovine
serum, 100 mg/mL streptomycin, and 100 IU/mL
penicillin at 37 °C in 5% CO2.
Macrophages were cultured at 37 °C in DMEM with
4 mM L-glutamine (Dutscher) supplemented with 10%
heat-inactivated fetal calf serum (Dutscher) and Hepes
10 mM (Dutscher), in a 5% CO2 atmosphere.
Mice and parasites
Six- to eight-week-old female BALB/c mice were
purchased from Shandong University Laboratory Animal
Centre (Jinan, China). All animal experiments were
approved with the Animal Ethics Committee of
Shandong University under Contract 2011–0015.
We used two strains of T. gondii (RH and PRU) in this
study. The low virulent strain (PRU strain) of T. gondii
was kept in our laboratory by passage of cysts in
Kunming mice. The tachyzoites of the RH strain of T.
gondii, which was preserved at −80 °C, were obtained by
passage on macrophages. About 1 × 104 tachyzoites of
intermediate virulence were collected from one 225-cm2
culture flask, corresponding to 1 μg of TE. Tachyzoitesof highly virulent T. gondii were collected to challenge
mice.
The construction of the expression plasmids
The T. gondii toxofilin gene coding sequence [GenBank:
AJ132777.2] was amplified by PCR from genomic para-
site DNA using the following specific primer pair.
Toxofilin for eukaryotic expression plasmid construc-
tion: forward primer: 5′-CGGGGTACCATGGCGCAAT
ACAAGTCACG-3’(Kpn I), reverse primer: 5’-CG GG
ATCCTTACGACGAGGGCATAGCG-3’(BamH I). Tox-
ofilin for prokaryotic expr -ession plasmid construction:
forward primer: 5′-CGGGGTACCATGGCGCAA TACAA
GTCACG-3’(Kpn I), reverse primer: 5′-CGGCGGCCGCT
TACGACGA GGGCATAGCG-3’′ (Not I) (recognition
sites for Kpn I, BamH I and Not I, respectively, are under-
lined). The amplified PCR products were cloned into the
eukaryotic expression vector pEGFP-C1 (TransGen, China)
and the prokaryotic expression plasmid pET-30a(+) to
formed a recombinant plasmid, pEGFP-toxofilin and
pET30-toxofilin.
pEGFP-toxofilin plasmids expression in vitro
pEGFP-toxofilin plasmids were transformed into
Escherichia coli DH5 by the way of hot shot (42 °C.). Ex-
pression of two genes in transformed DH5α cells was
screened on LK solid medium, followed by choosing a
single colony to cultivate for harvest of recombinant
plasmids. All the recombinant plasmids were extracted
by an endotoxin-free plasmid purification kit (Tiangen,
China) and stored at −20 °C until use. The plasmids
concentrations were determined by A260/A280
measurement.
HEK239T cells grown in 6-well plates were respect-
ively transfected with recombinant eukaryotic plasmid
(pEGFP-toxofilin) or an empty plasmid pEGFP-C1
with the assistance of LipofectamineTM 2000 reagent
(Invitrogen, USA) in accordance with the manufac-
turer’s instructions. Protein expression in vitro was
observed by specific green fluorescence on HEK293T
cells after incubation for 24 h at 37 °C in a 5% CO2
incubator. At 36 h post-transfection, the cells were
rinsed twice with PBS, handled with lysis buffer
(Sigma, USA), and centrifuged at 16,000 × g for
30 min. The lysates of transfected cells were analyzed
by western blotting.
Expression and purification of pET30- toxofilin in bacteria
Escherichia coli DH5α strain cells were transformed by
recombinant pET30-toxofilin and grown in Luria Bertani
(LB) at 37 °C until the cell density reached an absorb-
ance of 0.6 (at λ = 600 nm). Synthesis of recombinant
pET30-toxofilin protein was induced with 1 mM
isopropyl-β-D-thiogalactoside (IPTG) for 6 h and 8 h at
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were lysed and the protein was purified. The endotoxin
was removed with the ToxinEraser™ Endotoxin Removal
Kit and measured by the Chromogenic End-point Endo-
toxin Assay Kit (Chinese Horseshoe Crab Reagent
Manufactory, Xiamen, China). Expression of the pET30-
toxofilin protein was analyzed by western blotting and
kept at −80 °C for further use.
Immunization and challenge
The immunization experiments that pEGFP-toxofilin
DNA was used as the vaccine were performed in 6- to
8-week-old female BALB/c mice, which were randomly
divided into eight groups (n = 25/group). Mice were
injected intramuscularly three times at fortnightly
intervals with the following four experimental immuni-
zations: non-adjuvanted toxofilin (50 μg toxofilin DNA
+ 100 μL PBS/mouse); alum-toxofilin (50 μg toxofilin
DNA + 50 μg alum + 50 μL PBS/mouse); MPLA-toxofilin
(50 μg toxofilin DNA + 50 μg MPLA + 50 μL PBS/
mouse); alum-MPLA-toxofilin (50 μg toxofilin DNA +
50 μg MPLA + 50 μL PBS/mouse); and 4 control groups,
with mice receiving 150 μL PBS, 150 μg alum, 150 μg
MPLA, 150 μg alum-MPLA. The blood of mice in each
group was collected at 0, 2, 4, and 6 weeks by orbital
blood and sera were stored at −20 °C until used for sub-
sequent analysis. Two weeks after the final inoculation,
12 mice in each group were challenged i.p. with 1 × 104
T. gondii RH strain tachyzoites, and the remaining mice
in all groups were inoculated with 20 cysts of the attenu-
ated virulent PRU strain orally. The individual survival
time injected with RH strain along with the overall per-
centage survival were recorded. The dead mice infected
RH strain were treated by high pressure sterilization and
sent to the animal experiment center for further pro-
cessing. The brain cysts were determined one month
later after the challenge infection with 20 cysts of the
attenuated virulent PRU strain orally for a one time.
Each brain was homogenized in 2 ml PBS, and the mean
number of cysts per brain was calculated. This analysis
was performed in three independent experiments.
Determination of antibodies by ELISA
Anti-T. gondii IgG, IgG1, and IgG2a antibodies were
detected using enzyme-linked immunosorbent assay
(ELISA) in accordance with the manufacturer’s in-
structions (Southern Biotech Co., Ltd, Birmingham,
USA). Briefly, microtiter 96-well plates were coated
overnight at 4 °C with pET30-toxofilin protein anti-
gen (diluted in 0.1 M carbonate buffer (pH 9.5) for
optimal binding. The plates were washed three times
with PBS containing 0.05% Tween20 (PBST) and then
blocked with 1% bovine serum albumin for 1 h at
37 °C with gentle shaking. After three washes withPBST, the plates were incubated with mouse sera
diluted 1:100 in PBS for 1 h, followed by incubation
with goat anti-mouse IgG, IgG1, or IgG2a secondary
antibodies for 1 h to detect the target antibody and
isotype control, respectively. Finally, the immune
enzymatic reaction complexes were visualized by in-
cubating with ortho-phenylenediamine (Sigma, USA)
and 0.15% H2O2 for 30 min. Reactions were stopped
by adding 2 M H2SO4, and the results were read at
OD450 nm using an ELISA plate reader. An average
of three independent ELISAs for each serum sample
was recorded.Cytokine assays
Cytokine levels were determined as previously de-
scribed [16]. Three mice per group were euthanized
and their splenocytes aseptically harvested after two
weeks after the last immunization, Cells were dispensed
into 96-well plates at a density of 5 × 105 cells at 37 °C
with 95% relative humidity in 5% CO2. Cell-free super-
natants were harvested and assayed for interleukin (IL)-
4, IL-10, and IFN-γ at 24 h, 72 h, and 96 h, respectively,
using a commercial ELISA kit. All measurements were
run in triplicate.Identification of CD4+ and CD8+ T cells by flow
cytometry
By flow cytomety analysis, the percentage of CD4+ and
CD8+ T cell in spleen were determined. The cell
concentration was adjusted to 1 × 106 cells/ml in PBS
containing 2% FBS. After incubation with FITC-
conjugated anti-mouse CD4+ monoclonal antibody
(mAb), PE-conjugated anti-mouse CD3+ mAb and
Cy5.5-conjugated anti-mouse CD8+ mAb (eBioscience)
at 4 °C for 30 min in the dark. The cultures were washed
by 2 mL PBS and the suspensions were analyzed using
SYSTEM II software (Coulter) through FACScan flow
cytometer (BD Biosciences, San Jose, CA, USA).Statistical analyses
All statistical analyses and graph plotting were per-
formed by SPSS13.0 Data Editor and the differences
in the data (antibody responses, lymphoproliferation
assays, cytokine production and brain cyst burden)
between all the groups were compared by one-way
analysis of variance (ANOVA). Tukey’s studentized
range test was used for post-test comparisons.
Survival rates for the experimental and control mice
were compared using the Kaplan–Meier method and
compared with the log-rank test. The differences were
considered significantly if P < 0.05.
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Bioinformatic analysis
The toxofilin protein of T. gondii (Tg-toxofilin) is a 245
amino acid protein with a molecular weight of
27.1317 kDa. Its physical and chemical properties include
a theoretical PI of 9.57, an instability index of 60.41, an
aliphatic index of 84.98, and a grand average of hydro-
pathicity of −0.63. For four different T. gondii strains, the
protein sequence alignment is shown in Fig. 1. and share
96.53% similarity, with toxofilin of the T. gondii RH strain
sharing 100%, 91.84%, and 94.29% sequence identity with
GT1, ME49, and VANDPR strains, respectively.Secondary structure and 3D modeling
B-cell epitopes are the portions of antigens that are
recognized by the variable regions of antibodies. Accur-
ately predicting epitopes is of great help for designing
immunogenic peptides and new vaccines. In the present
study, the DNASTAR software was used to predict anti-
genic index and surface probability, as shown in Fig. 2.
Based on this analysis, the peptides with good hydrophil-
icity, high accessibility, high flexibility, and strong
antigenicity were chosen as antigen epitopes. To further
confirm these results, the DNAMAN software was used
to analyze these sequences and nine potential epitopes
were chosen with the highest antigen index scores, as
shown in Table 1.
A potentially antigenic region of a protein increases
the epitope prediction and promote a better understand-
ing the 3D structure, contributing to the elucidation of
the relationship between structure and function. The
SOPMA and I-TASSER online services were used toFig. 1 Alignment of toxofilin protein sequences from toxoplasma strains. B
missing amino acidpredict the 3D structures of toxofilin alone and in com-
plex with mammalian actin (Fig. 3 A1 and A2).Identification of the Th-cell epitopes
The Th-cell epitopes identified on toxofilin by bio-
informatic analyses reportedly have the ability to bind
strongly to MHC class II molecules (Table 2). It is
known that the binding force increases can influence
Th-cell differentiation and promote more cells to
differentiate into Th-1 cells [15]. Therefore, we specu-
late that toxofilin has the potential to induce Th-1
cell-mediated immune responses.Identification of restructuring eukaryotic, prokaryotic and
pro expression plasmids
Forty-eight hours after transfection of HEK cells, the
presence of pEGFP-toxofilin or pEGFP-C1 was deter-
mined by fluorescence microscopy. As shown in
Fig. 4(A1) and (A2), green fluorescence was observed
in HEK293T cells transfected with pEGFP-toxofilin
and pEGFP-C1, whereas there was no signal in the
untransfected cells Fig. 4 (A3). Western blot analysis
of these proteins was shown in Fig. 4B; a specific
protein band (about 27 kDa) was recognized in cells
transfected with pEGFP-toxofilin by incubation with a
T. gondii antibody (lanes 2), whereas the negative
controls transfected with empty pEGFP vector showed
no specific bands upon incubation with a T. gondii
antibodies (lane 1). The purified recombinant pET30-
toxofilin vector was used to produce toxofilin protein
antigen. Western blot technique by using a T. gondiilues letters indicate amino acid differences, while … represents a
Fig. 2 Prediction of B-cell epitopes in the toxofilin protein based on DNAStar. The linear-B cell epitopes of toxofilin predicted by DNASTAR in
flexibility, hyd- rophilicity, surface probability and antigenicity index rules. The prediction was run for three times
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(lane4).
Determination of antibody responses in immunized
BALB/c mice
Sera induced in T. gondii immunized mice were tested
post-immunization by standard ELISA at weeks 0, 2, 4,
and 6. As shown in Fig. 5, significantly higher levels of
total IgG antibodies were detected in the sera of mice
immunized in the experimental groups compared with
the control immunized groups, especially after the third
immunization. Moreover, the mean titers of IgG anti-
bodies induced in the alum-MPLA- toxofilin group were
significantly higher after both priming and booster
immunization compared with the levels induced by tox-
ofilin alone DNA vaccine or with single adjuvant. In
contrast, the total IgG levels were similar between alum-
toxofilin and MPLA-toxofilin groups.Table 1 Analysis of linear-B cell antigenic epitopes on Tg-toxofilina
Order Position Sequence Scoreb
1 5-31 KSRPLAAFLLLITVGSLLTASESVQLS 1.184
2 82-105 IAGQAKAAALQTVHQLGAVALTPE 1.153
3 107-115 AKAALLDEL 1.089
4 175-190 QRRHYHVTKQAALAGQ 1.096
5 199-211 SGALQSGAVKTAI 1.095
6 233-242 SGALQSGAVKTAI 1.095
7 71-78 ELGLLRPT 1.072
8 62-69 SPSVAARQ 1.068
9 137-158 AYEQVQRDLSQLSPETKALLLE 1.067
aThe prediction was run for three times. Two or more amino acids condense
into a peptide
bHigh score = high bindingSerum levels of IgG1 and IgG2a, which are character-
istic of Th2 and Th1 responses respectively, were ana-
lyzed by ELISA after the last immunization. As shown in
Fig. 6, the non-adjuvanted toxofilin DNA vaccine group
demonstrated similar levels of IgG1 and higher levels of
IgG2a compared with control groups. However, com-
pared with the non-adjuvanted toxofilin DNA vaccine,
the alum-toxofilin group showed a significant improve-
ment in the IgG1 level, indicative of a Th2-skewed im-
mune response. Conversely, the MPLA-toxofilin group
induced higher levels of IgG2a, and is therefore more
likely to induce a Th1-biased immune response. Import-
antly, significantly higher serum levels of IgG2a and a
slight increase in IgG1 were detected in the alum-
MPLA-toxofilin immunized group when compared with
other groups, suggesting that this combination of DNA
vaccine and adjuvant may be most efficacious in raising
a Th1 response following immunization.
Cytokine production by spleen cells
The sera samples collected were used to measure the
levels of IFN-γ, IL-4, and IL-10 induced by
immunization with toxofilin DNA vaccine in the pres-
ence or absence of adjuvants. Generally, IFN-γ favors
Th1-type immune responses, whereas IL-4 and IL-10
drive Th2 skewing [16]. As demonstrated in Table 3,
values of IFN-γ in toxofilin DNA vaccine, alum- toxofi-
lin, and MPLA- toxofilin immunization groups were
607.29 ± 63.09 pg/mL, 694.39 ± 88.64 pg/mL, and
3043.54 ± 350.72 pg/mL, respectively, which were signifi-
cantly higher than in the control group of PBS (48.54 ±
2.40 pg/mL), alum (49.58 ± 2.37 pg/mL), MPLA (218.34
± 21.34 pg/mL), alum-MPLA (267.34 ± 24.35 pg/mL).
Furthermore, the highest level of IFN-γ was detected at
3859.42 ± 380.67 pg/mL in the alum-MPLA-toxofilin
Fig. 3 Toxofilin 3D structure predictions. (A1) 3D structure of Tg-toxofilin 3D model with the highest score for the Tg-toxofilin protein was selected
(1: Alpha helix, 2: Random Coil, 3: Extend Strand, 4: Beta Turn). (A2) Complex of Mammalian Actin With Toxofilin From Toxoplasma gondii, Toxofilin from
toxoplasma gondii forms a ternary complex with an antiparallel actin dimer. The model was viewed by VMD software and colored to illustrate the
different protein components (5: Actin, Alpha skeletal Muscle, 6: toxofilin)
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detected in the alum-toxofilin, MPLA- toxofilin, and
alum-MPLA-toxofilin groups. However, significantly
higher concentrations of both cytokines (IL-4 236.473 ±
24.05 pg/mL, IL-10 212.32 ± 30.27 pg/mL) were detected
in the alum-toxofilin group, compared with the other
groups.T lymphocyte subsets analysis
The Splenocyte proliferation was evaluated in mice two
weeks after the last immunization. As shown in Table 4,
CD8+ T cells accounted for a significantly higher pro-
portion than that in the control groups and a significant
higher percentage of CD8+ T cells were dramatically in-
creased in the alum-MPLA- toxofilin mixture group.
The result also showed same statistically difference in
the percentage of CD4+ T cells between experimental
groups (toxofilin, alum-toxofilin, MPLA-toxofilin andTable 2 Ligation strength analysis of Tg-toxofilin for MHC class
II molecules using SYFPEITHIa
MHC II Alleleb Start-Stopc Sequence Percent: e Rankd
HLA-DRB1*01:01 91-105 LQTVHQLGAVALTPE 0.39
HLA-DRB1*01:01 9-23 LAAFLLLIVGSLLT 0.42
H2-IAb 78-92 EERLIAGQAKAAALQ 3.04
H2-IAb 96-110 QLGAVALTPEQAKAA 6.58
H2-IAd 178-192 HYHVTKQAALAGQIL 0.13
H2-IAd 231-245 QHASQLKKVGAMPSS 0.62
H2-IEd 169-183 KARKLFQRRHYHVTK 13.80
H2-IEd 28-42 VQLSEGMKRLSMRGR 21.98
aThe prediction was run for three times
bH2-IAb, H2-IAd and H2-IEd alleles are mouse MHC class II molecules; the
HLADRB1*01:01 allele is a human MHC class II molecule
cWe chose 15 amino acids for analysis each time
dLow percentile = high level binding, high percentile = low level bindingalum -MPLA -toxofilin immunization groups) and the
control groups.
Protective immunity analysis against challenge with T.
gondii RH strain
The survival curves against acute toxoplasmosis are
shown in Fig. 7, and notably prolonged survival times
were recorded in the experimentally immunized mice in
comparison with the control groups (P < 0.05). Among
the different experimental groups, mice vaccinated with
the alum-MPLA-toxofilin had obviously prolonged sur-
vival, with 50% of mice surviving to day 24 of challenge.
“One month after challenge with 20 cysts of PRU
strain of T. gondii, surviving mice were killed and brain
cysts were enumerated.” The cyst number (1034.49 ±
45.87) in the mice immunized with alum-MPLA-
toxofilin was significantly reduced compared to other
groups (Table 5).
Discussion
Bioinformatics has been regarded as crucial tool in the
analysis of the protein characteristics including to the
protein epitopes [27]. In this study, bioinformatic ana-
lysis has been applied to predict toxofilin antigens using
relatedness software and online services. As shown in
Fig. 1, the results of our analysis suggested that the toxo-
filin sequence is conserved between different strains of
T. gondii. In addition, the 3D structure of toxofilin was
constructed and several promising linear B- and Th-cell
epitopes were identified. According to the data analysis,
we concluded that toxofilin protein may be regarded as
a potential antigen and we have successfully constructed
an antigen-encoding plasmid, pEGFP-toxofilin. To fur-
ther confirm the antigenicity of pEGFP-toxofilin after
parasitic infection, the immune response (cellular and
humoral) was assessed by immunization and lethal
challenge.
Fig. 4 Green fluorescent microscopy image of HEK293T cells and western blotting. (A1) HEK293 cells transfected with pEGFP-Tgtoxofilin under
blue light. (A2) HEK293 cells transfected with pEGFP. (A3) non-transfected HEK293 cells. (B) Western blot analysis of pEGFP-toxofilin protein in
transfected HEK293 cells, PET-30 toxofilin protein in bacterial, respectively. (B1) In HEK 293 cells, the expressed proteins were reacted with a T.
gondii antibody (lanes 2) and the control empty pEGFP plasmid-transfected cells did not show any band with a T. gondii antibody (lane 1). (B2)
PET-30 toxofilin protein were reacted with a T. gondii antibody (lane 4), the empty pET30a vector showed no specific bands with a T. gondii
antibody (lane 3). (lane M) Respresents protein molecular weight markers
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and persistent Th1 immune response. IFN-γ which is
Th1-type cytokine has been regarded as a decisive medi-
ator of resistance to T. gondii [28]. In addition, the prin-
cipal source of IFN-γ is from both CD8+ T cells and
CD4+ T cells [29]. In this study, the percentage of CD8+Fig. 5 Measurement of specific IgG antibodies in sera of immunized
mice. Sera were collected one day prior to each immunization and
determined by ELISA. Results are shown as means of OD 490 nm ±
SD and statistical differences (P < 0.05) are indicated by*
Fig. 6 Distribution of IgG subtypes IgG1 and IgG2a in immunized
mice. The levels of IgG subtypes IgG1 and IgG2a in sera of mice
2 weeks after the last immunization were analyzed by ELISA. Results
are expressed as means of the OD 490 ± SD and statistically
significant differences (P < 0.05) are indicated by an asterisk (*)
Table 3 Cytokine production by splenocytea cultures from
immunized BALB/c mice
Groups Cytokine Production (pg/ml)b
IFN-γ IL-4 IL-10
PBS 48.54 ± 2.40 38.79 ± 2.28 44.70 ± 2.70
Alum 49.58 ± 2.37 110.49 ± 10.38 123.45 ± 13.48
MPLA 218.30 ± 21.34 40.35 ± 2.34 51.46 ± 3.21
alum-MPLA 267.34 ± 24.35 78.34 ± 7.34 58.46 ± 5.34
pEGFP- toxofilin 607.29 ± 63.09* 37.61 ± 2.87 34.70 ± 3.04
alum-toxofilin 694.39 ± 88.64* 236.47 ± 24.05^ 212.32 ± 30.27^
MPLA-toxofilin 3043.54 ± 350.72*# 93.58 ± 10.31 85.43 ± 9.72
alum-MPLA-
toxofilin
3859.42 ± 380.67*# 103.43 ± 24.43 115.32 ± 30.31
aSplenocytes from 3 mice per group two weeks after the final immunization
bValues for IFN-γ at 96 h, IL-4 at 24 h, IL-10 at 72 h and are expressed
as mean ± SD
*Compared with PBS, alum, MPLA, aum-MPLA, P < 0.05
#Compared with alum-toxofilin or pEGFP-toxofilin groups, P < 0.05
^Compared with other groups
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suggesting that the effect of synergy between CD8+ and
CD4+ T cells may contribute to the higher concentration
of IFN-γ. Previous studies have shown IFN-γ can also
contribute to tryptophan degradation in a large number
of infected cell types [29]. As shown in Table 3 and
Table 4, by stimulation with the pEGFP-toxofilin DNA
vaccine, a significant increase of IFN-γ, CD8+ T cells
and CD4+ T cells, was induced in comparison with the
control groups. Moreover, previous studies have sug-
gested that the level of Th2-associated cytokines, IL-4
and IL-10, produced during T. gondii infection also play
an important role in the immune response. In the
present study, a slight reduction of both IL-4 and IL-10
was also observed in the pEGFP-toxofilin DNA vaccineTable 4 Percentages of T lymphocyte subsets in immunized
micea by flow cytometry
Groups CD3+ CD4+ CD8− (%) CD3+ CD8+ CD4− (%)
PBS 15.31 ± 0.12 7.35 ± 0.18
alum 17.34 ± 0.34 9.62 ± 0.29
MPLA 17.92 ± 0.25 9.08 ± 0.24
alum-MPLA 18.49 ± 0.19 10.13 ± 0.30
pEGFP- toxofilin 20.17 ± 0.53* 12.48 ± 0.43*
alum-toxofilin 21.37 ± 0.76* 12.98 ± 0.45*
MPLA-toxofilin 27.46 ± 0.97*# 17.39 ± 0.98*#
alum-MPLA-toxofiln 32.38 ± 1.19*# 20.68 ± 1.37*#
aSplenocytes from 3 mice per group at the fourth week after the
final immunization
*Compared with PBS, alum, MPLA, alum-MPLA. P <0.05
#Compared with alum-toxofilin or pEGFP-toxofilin groups, P <0.05
Results are presented as means ± SD of three replicate determinationsgroup compared with the other groups, suggesting
impaired Th2 responses compared with control groups.
Besides cellular immune responses, humoral immunity
resulting in total IgG antibody plays an important role in
controlling T. gondii infection [30]. In this report, we an-
alyzed the humoral response after vaccination with
pEGFP-toxofilin DNA vaccine and found that immu-
nized mice presented high titers of total specific IgG in
contrast to the control groups. Along with macrophages,
specific IgG antibodies can protect the host from
chronic T. gondii infections and cyst amount. Our obser-
vations were further validated by characterization of the
mixed Th1/Th2 response. High IgG1 levels mainly indi-
cate Th2 responses while elevated IgG2a levels favor
development of Th1 responses. As shown in Fig. 6, we
found higher levels of IgG2a and slightly lower IgG1
titers by the pEGFP-toxofilin DNA vaccine, indicating
that our vaccine induced immune responses more biased
towards Th1 in BALB/c mice, suggestive of protection
against toxoplasmosis and therefore, represents a poten-
tial vaccine candidate.
To strengthen and boost the level of molecular vac-
cines immune responses, adjuvant is a powerful tool to
enhance the immunogenicity of DNA vaccines [31]. We
evaluated the immunogenicity and protective capacity of
pEGFP-toxofilin DNA vaccine either alone, with the sin-
gle adjuvants alum or MPLA, or combined alum-MPLA
adjuvants. Incorporation of alone or mixed adjuvants
significantly boosted the production of IgG titers follow-
ing vaccination with the pEGFP-toxofilin DNA vaccine,
inducing differential skewing of protective immunity
compared with the non-adjuvanted toxofilin antigen,
and to each adjuvant, as alum and MPLA induce differ-
ent biases in the immune response [17, 18]. The alum-
toxofilin group increased IgG1 levels compared with
non-adjuvanted toxofilin, skewing the immune response
towards a Th2 response associated with strong produc-
tion of the IL-4, IL-10, and the IgG1 antibody subtype.
Conversely, the MPLA adjuvant is known to induce a
Th1-biased immune response [32], resulting in signifi-
cantly increased specific serum IgG2a isotype antibodies
and higher levels of Th1 cytokines. Importantly, the
alum-MPLA-toxofilin could effectively lead to a shift
from a Th2-skewed immune response towards a Th1
profile and, ultimately, to a balanced immune response
compared with the use of a single adjuvant.
For protective efficacy of DNA vaccines against T. gon-
dii challenge, the most direct parameter including to
survival time, brain cysts load, brain cysts reduction rate,
and protection rate should be considered [33]. The
present study revealed that the alum-MPLA-toxofilin
group could prolong the mice survive time as shown in
Fig. 7, significantly reducing the brain cyst burden
shown in Table 5. However, our DNA vaccine did not
Fig. 7 Survival curves of the vaccinated BALB/c following Toxoplasma gondii challenge infections. The mice in eight groups of mice were
challenged with 1 × 104 tachyzoites of the virulent RH strain of T. gondii 2 weeks after the last immunization (n = 12) per group
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future, evaluating the efficacy of vaccines from different
sources remains a new and promising strategy [34]. Fur-
ther studies are needed to continue to develop DNA
vaccines to improve the immunization efficacy against
toxoplasmosis.Conclusions
In the present study, we use bioinformatic approaches to
analyze the antigenicity of T. gondii toxofilin antigen.
Therefore, toxofilin could be regared as a novel and
strong DNA vaccine candidate against toxoplasmosis. At
the same time, immunization with the alum-MPLATable 5 Mean cyst burden per mouse brain 4 weeks after
challenge with 20 cysts of Toxoplasma gondii PRU strain per
mouse
Challenged groupa Brain cysts per mouse (mean ± SD)b
PBS 3042.43 ± 115.17
alum 2834.45 ± 100.89
MPLA 2767.36 ± 103.45
alum-MPLA 2532.56 ± 99.45
pEGFP-toxofilin 2048.79 ± 87.44*
alum-toxofilin 1764.17 ± 78.45*
MPLA-toxofilin 1563.42 ± 80.48*
alum-MPLA-toxofiln 1034.49 ± 45.87*#
a10 mice from each group were challenged intragastrically by 20 cysts
2 weeks after the last immunization. All samples were run for three times
bThe mean number of cysts of each group was obtained from every mice
brain cysts in the group
*Compared with PBS, alum, MPLA, alum-MPLA, P < 0.05
#Compared with pEGFP- toxofilin, alum-toxofilin and MPLA-toxofilin, P < 0.05mixture as an adjuvant, in combination with the pEGFP-
toxofilin DNA vaccine, can enhance cellular immunity
and shift the immune response towards a Th1 profile.
Furthermore, the alum-MPLA-toxofilin can also induce
partial protective immunity in the murine model.
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